Last updated on January 2020

GB001 in Adult Subjects With Moderate to Severe Asthma

Brief description of study

A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 when added to standard-of care (SOC) asthma maintenance therapy in adults with moderate to severe asthma and an eosinophilic phenotype with respect to asthma worsening at the end of 24 weeks of treatment.

Clinical Study Identifier: NCT03683576

Find a site near you

Start Over